Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Primary malignant pericardial tumour in Lynch syndrome.

Paolisso P, Saturi G, Foà A, Saponara M, Nannini M, Pantaleo MA, Leone O, Turchetti D, Calistri D, Savini C, Pacini D, Pizzi C, Galiè N.

BMC Cancer. 2020 Mar 6;20(1):191. doi: 10.1186/s12885-020-6677-y.

2.

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases.

Figlioli G, Kvist A, Tham E, Soukupova J, Kleiblova P, Muranen TA, Andrieu N, Azzollini J, Balmaña J, Barroso A, Benítez J, Bertelsen B, Blanco A, Bonanni B, Borg Å, Brunet J, Calistri D, Calvello M, Chvojka S, Cortesi L, Darder E, Del Valle J, Diez O; ENIGMA Consortium, Eon-Marchais S, Fostira F; GENESIS Study Collaborators, Gensini F, Houdayer C, Janatova M, Kiiski JI, Konstantopoulou I, Kubelka-Sabit K, Lázaro C, Lesueur F, Manoukian S, Marcinkute R, Mickys U, Moncoutier V; SWE-BRCA Group, Myszka A, Nguyen-Dumont T, Nielsen FC, Norvilas R, Olah E, Osorio A, Papi L, Peissel B, Peixoto A, Plaseska-Karanfilska D, Pócza T, Rossing M, Rudaitis V, Santamariña M, Santos C, Smichkoska S, Southey MC, Stoppa-Lyonnet D, Teixeira M, Törngren T, Toss A, Urioste M, Vega A, Vlckova Z, Yannoukakos D, Zampiga V, Kleibl Z, Radice P, Nevanlinna H, Ehrencrona H, Janavicius R, Peterlongo P.

Cancers (Basel). 2020 Jan 26;12(2). pii: E292. doi: 10.3390/cancers12020292.

3.

Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome.

Pirini F, Tedaldi G, Danesi R, Cangini I, Tumedei MM, Ferrari A, Vitali S, De Maio G, Terragna C, Solli V, Tebaldi M, Puccetti M, Zampiga V, Ravegnani M, Ulivi P, Falcini F, Martinelli G, Calistri D.

Int J Colorectal Dis. 2019 Nov;34(11):1999-2002. doi: 10.1007/s00384-019-03414-y. Epub 2019 Oct 26.

PMID:
31655866
4.

Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.

Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzani GN, Calistri D.

Cancers (Basel). 2019 Sep 11;11(9). pii: E1340. doi: 10.3390/cancers11091340.

5.

E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer.

Rossi T, Tedaldi G, Petracci E, Abou Khouzam R, Ranzani GN, Morgagni P, Saragoni L, Monti M, Calistri D, Ulivi P, Molinari C.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4452. doi: 10.3390/ijms20184452.

6.

Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.

Dhieb D, Belguith I, Capelli L, Chiadini E, Canale M, Bravaccini S, Yangui I, Boudawara O, Jlidi R, Boudawara T, Calistri D, Keskes LA, Ulivi P.

Cells. 2019 May 28;8(6). pii: E514. doi: 10.3390/cells8060514.

7.

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.

Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, Capalbo C, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L.

Int J Cancer. 2019 Jul 15;145(2):390-400. doi: 10.1002/ijc.32106. Epub 2019 Jan 24.

PMID:
30613976
8.

Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy.

Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco L, Coppa A, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P, Ottini L.

Front Oncol. 2018 Dec 4;8:583. doi: 10.3389/fonc.2018.00583. eCollection 2018.

9.

Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).

Chiadini E, Canale M, Delmonte A, Dazzi C, Casanova C, Capelli L, Mariotti M, Papi M, Gamboni A, Puccetti M, Bravaccini S, Dubini A, Calistri D, Crinò L, Ulivi P.

J Thorac Dis. 2018 Aug;10(8):4858-4864. doi: 10.21037/jtd.2018.07.22.

10.

Carcinosarcoma of the prostate: case report with molecular and histological characterization.

Salvi S, Casadio V, Martignano F, Gurioli G, Tumedei MM, Calistri D, Gunelli R, Costantini M.

Int J Biol Markers. 2018 Nov;33(4):540-544. doi: 10.1177/1724600818791463. Epub 2018 Aug 12.

PMID:
30101629
11.

Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis.

Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A, Casadei Gardini A, Frassineti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri D, Pasca MR.

Sci Rep. 2018 Jul 9;8(1):10329. doi: 10.1038/s41598-018-28671-9.

12.

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients.

De Matteis S, Molinari C, Abbati G, Rossi T, Napolitano R, Ghetti M, Di Rorà AGL, Musuraca G, Lucchesi A, Rigolin GM, Cuneo A, Calistri D, Fattori PP, Bonafè M, Martinelli G.

J Transl Med. 2018 Jun 20;16(1):172. doi: 10.1186/s12967-018-1545-0.

13.

MicroRNAs and CDH1 regulation in intestinal-type gastric cancer.

Molinari C, Rossi T, Abou Khouzam R, Ranzani G, Tedaldi G, Ulivi P, Morgagni P, Saragoni L, Monti M, Calistri D.

Ann Oncol. 2018 Jun;29 Suppl 5:v1-v2. doi: 10.1093/annonc/mdy151.003. Epub 2020 Jan 7. No abstract available.

14.

Stool DNA Integrity Method for Colorectal Cancer Detection.

Rengucci C, De Maio G, Menghi M, Calistri D.

Methods Mol Biol. 2018;1765:193-202. doi: 10.1007/978-1-4939-7765-9_12.

PMID:
29589309
15.

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR.

Molinari C, Abou Khouzam R, Salvi S, Rossi T, Ranzani GN, Calistri D.

J Vis Exp. 2018 Feb 5;(132). doi: 10.3791/57066.

16.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E.

Int J Mol Sci. 2018 Jan 20;19(1). pii: E307. doi: 10.3390/ijms19010307.

17.

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.

Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L.

Breast. 2018 Apr;38:92-97. doi: 10.1016/j.breast.2017.12.013. Epub 2018 Jan 4.

PMID:
29287190
18.

Serum and Plasma Copy Number Detection Using Real-time PCR.

Salvi S, Conteduca V, Martignano F, Gurioli G, Calistri D, Casadio V.

J Vis Exp. 2017 Dec 15;(130). doi: 10.3791/56502.

19.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, Calistri D, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG.

Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11.

20.

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A.

Int J Mol Sci. 2017 Jun 9;18(6). pii: E1240. doi: 10.3390/ijms18061240.

21.

Right- versus left-side metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy.

Ulivi P, Scarpi E, Valgiusti M, Casadei Gardini A, Marisi G, Calistri D, Ragazzini A, Chiadini E, Capelli L, Frassineti Giovanni L, Amadori D, Passardi A.

Ann Oncol. 2017 Jun;28 Suppl 3:iii8. doi: 10.1093/annonc/mdx263.019. No abstract available.

22.

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.

Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, Falcini F, Amadori D, Calistri D.

Oncotarget. 2017 Jul 18;8(29):47064-47075. doi: 10.18632/oncotarget.16791.

23.

BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.

Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, Capizzi E, Santini D, Miccoli S, Medici V, Danesi R, Marchi I, Zampiga V, Fiorentino M, Ferrari S, Turchetti D.

Oncotarget. 2017 Apr 4;8(14):22640-22648. doi: 10.18632/oncotarget.15151.

24.

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

Maltoni R, Casadio V, Ravaioli S, Foca F, Tumedei MM, Salvi S, Martignano F, Calistri D, Rocca A, Schirone A, Amadori D, Bravaccini S.

Oncotarget. 2017 Mar 7;8(10):16642-16649. doi: 10.18632/oncotarget.15120.

25.

Cell-Free DNA Integrity Analysis in Urine Samples.

Casadio V, Salvi S, Martignano F, Gunelli R, Ravaioli S, Calistri D.

J Vis Exp. 2017 Jan 5;(119). doi: 10.3791/55049.

26.

What influences preneoplastic colorectal lesion recurrence?

De Maio G, Zama E, Rengucci C, Calistri D.

Oncotarget. 2017 Feb 14;8(7):12406-12416. doi: 10.18632/oncotarget.13628. Review.

27.

Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.

Abou Khouzam R, Molinari C, Salvi S, Marabelli M, Molinaro V, Orioli D, Saragoni L, Morgagni P, Calistri D, Ranzani GN.

Oncotarget. 2017 Mar 21;8(12):18811-18820. doi: 10.18632/oncotarget.13401.

28.

Cell-free DNA as a diagnostic marker for cancer: current insights.

Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D, Casadio V.

Onco Targets Ther. 2016 Oct 25;9:6549-6559. eCollection 2016. Review.

29.

The potential use of urine cell free DNA as a marker for cancer.

Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U, Conteduca V, Casadio V.

Expert Rev Mol Diagn. 2016 Dec;16(12):1283-1290. Epub 2016 Nov 10. Review.

PMID:
27796148
30.

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P.

Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25.

31.

Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.

Zampiga V, Danesi R, Tedaldi G, Tebaldi M, Cangini I, Pirini F, Pittureri C, Amaducci E, Guidi L, Faedi M, Amadori D, Falcini F, Calistri D.

Int J Biol Markers. 2016 Dec 23;31(4):e461-e465. doi: 10.5301/jbm.5000227.

PMID:
27516001
32.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

Salvi S, Casadio V, Conteduca V, Lolli C, Gurioli G, Martignano F, Schepisi G, Testoni S, Scarpi E, Amadori D, Calistri D, Attard G, De Giorgi U.

Oncotarget. 2016 Jun 21;7(25):37839-37845. doi: 10.18632/oncotarget.9341.

33.

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.

Martignano F, Gurioli G, Salvi S, Calistri D, Costantini M, Gunelli R, De Giorgi U, Foca F, Casadio V.

Dis Markers. 2016;2016:4358292. doi: 10.1155/2016/4358292. Epub 2016 Aug 10.

34.

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

Gurioli G, Salvi S, Martignano F, Foca F, Gunelli R, Costantini M, Cicchetti G, De Giorgi U, Sbarba PD, Calistri D, Casadio V.

J Transl Med. 2016 Aug 30;14(1):249. doi: 10.1186/s12967-016-1014-6.

35.

Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.

Capelli L, Petracci E, Quagliuolo V, Saragoni L, Colombo P, Morgagni P, Calistri D, Tomezzoli A, Di Cosmo M, Roviello F, Vindigni C, Coniglio A, Villanacci V, Catarci M, Coppola L, Alfieri S, Ricci R, Capella C, Rausei S, Gulino D, Amadori D, Ulivi P; Italian Gastric Cancer Research Group (GIRCG).

Eur J Surg Oncol. 2016 Aug;42(8):1206-14. doi: 10.1016/j.ejso.2016.05.022. Epub 2016 May 30.

PMID:
27265040
36.

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.

Molinari C, Salvi S, Foca F, Teodorani N, Saragoni L, Puccetti M, Passardi A, Tamberi S, Avanzolini A, Lucci E, Calistri D.

Onco Targets Ther. 2016 May 6;9:2735-42. doi: 10.2147/OTT.S105760. eCollection 2016.

37.

Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.

Bonanno L, Calabrese F, Nardo G, Calistri D, Tebaldi M, Tedaldi G, Polo V, Vuljan S, Favaretto A, Conte P, Amadori A, Rea F, Indraccolo S.

Lung Cancer. 2016 Jun;96:52-5. doi: 10.1016/j.lungcan.2016.03.009. Epub 2016 Mar 25.

PMID:
27133750
38.

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.

Brigliadori G, Foca F, Dall'Agata M, Rengucci C, Melegari E, Cerasoli S, Amadori D, Calistri D, Faedi M.

J Neurooncol. 2016 Jun;128(2):333-9. doi: 10.1007/s11060-016-2116-y. Epub 2016 Mar 30.

PMID:
27029617
39.

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A.

Clin Lung Cancer. 2016 Sep;17(5):384-390. doi: 10.1016/j.cllc.2015.11.004. Epub 2015 Dec 1.

PMID:
26712101
40.

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Salvi S, Conteduca V, Gurioli G, Calistri D, Casadio V, De Giorgi U.

Mol Diagn Ther. 2016 Feb;20(1):1-12. doi: 10.1007/s40291-015-0169-9. Review.

PMID:
26518421
41.

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.

Salvi S, Gurioli G, Martignano F, Foca F, Gunelli R, Cicchetti G, De Giorgi U, Zoli W, Calistri D, Casadio V.

Dis Markers. 2015;2015:574120. doi: 10.1155/2015/574120. Epub 2015 Aug 27.

42.

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.

Pasini A, Delmonte A, Tesei A, Calistri D, Giordano E.

Drugs. 2015 Oct;75(15):1757-71. doi: 10.1007/s40265-015-0461-3. Review.

PMID:
26347133
43.

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.

Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D.

J Transl Med. 2015 Aug 11;13:258. doi: 10.1186/s12967-015-0619-5.

44.

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U.

Br J Cancer. 2015 May 12;112(10):1717-24. doi: 10.1038/bjc.2015.128. Epub 2015 Apr 21.

45.

ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.

Bravaccini S, Tumedei MM, Ulivi P, Zoli W, Calistri D, Candoli P, Amadori D, Puccetti M.

Cytopathology. 2016 Apr;27(2):103-7. doi: 10.1111/cyt.12237. Epub 2015 Mar 10.

PMID:
25757141
46.

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab.

Chiadini E, Scarpi E, Passardi A, Calistri D, Valgiusti M, Saragoni L, Zoli W, Amadori D, Ulivi P.

Oncol Lett. 2015 Mar;9(3):1432-1438. Epub 2015 Jan 14.

47.

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C.

Int J Mol Sci. 2014 Dec 31;16(1):747-57. doi: 10.3390/ijms16010747.

48.

Clinical and genetic factors related to cancer-induced bone pain and bone pain relief.

Scarpi E, Calistri D, Klepstad P, Kaasa S, Skorpen F, Habberstad R, Nanni O, Amadori D, Maltoni M.

Oncologist. 2014 Dec;19(12):1276-83. doi: 10.1634/theoncologist.2014-0174. Epub 2014 Oct 23.

49.

Improved stool DNA integrity method for early colorectal cancer diagnosis.

Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, Calistri D.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2553-60. doi: 10.1158/1055-9965.EPI-14-0379. Epub 2014 Aug 15.

50.

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.

Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C, Foschi G, Tumedei MM, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W, Calistri D.

J Exp Clin Cancer Res. 2014 Aug 5;33:65. doi: 10.1186/s13046-014-0065-x.

Supplemental Content

Loading ...
Support Center